Medigen (2)

Executive Summary

Medigen Biotechnology Corp. is a Taiwan-based integrated biomedical company focused on developing innovative therapies for oncology, infectious diseases, ophthalmology, and liver disorders. Since its founding in 2020, the company has rapidly built a diversified portfolio spanning new drug development, molecular diagnostics, vaccine technologies, and generic medicines. With a commercial-stage presence and a public listing, Medigen leverages its expertise in areas of high unmet medical need across Asia. Its emphasis on oncology and liver diseases positions it well in a growing regional market, supported by both proprietary drug candidates and commercialized vaccines.

Upcoming Catalysts (preview)

• Q3 2026Regulatory approval of liver cancer therapy in Taiwan70% success
• Q4 2026Licensing agreement for vaccine platform technology60% success
• Q1 2027Phase 3 topline results for lead oncology candidate55% success